tem cell scientists scored what at first appeared an easy win for regenerative medicine when they discovered mesenchymal stem cells several decades ago. These cells, found in bone marrow, can give rise to fat, bone, and muscle tissue, and have been used in hundreds of clinical trials for tissue repair. Unfortunately, the results of these trials have been underwhelming. One problem is that these stem cells don’t stick around in the body long enough to benefit patients.
But Harvard Stem Cell Institute (HSCI) scientists at Boston Children’s Hospital aren’t ready to give up. A research team led by Juan Melero-Martin
Stem cells from the ovaries of reproductive age women can give rise to cells that appear to be mature oocytes, suggesting that women can produce more eggs than the batch they are born with. The findings, reported in the March 2012 issue of Nature Medicine, open the door to a new generation of assisted fertility treatments.
Germline stem cells that produce oocytes in vitro and fertilization-competent eggs in vivo have been identified in and isolated from adult mouse ovaries. Here we describe and validate a fluorescence-activated cell sorting-based protocol that can be used with adult mouse ovaries and human ovarian
The U.S. Food and Drug Administration has approved the start of a mid-stage clinical trial of an adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS) according to its developer, BrainStorm Cell Therapeutics Inc. The Phase II clinical trial will be launched initially at UMass Medical School and Massachusetts General Hospital in Boston.
BrainStorm, an Israel-based biotech company developing stem cell technology to provide treatments for currently incurable neurodegenerative diseases, has been working with Robert H. Brown Jr., DPhil, MD, the Leo P. and Theresa M. LaChance Chair in Medical Research and chair and professor of neurology, to
In a breakthrough, Harvard scientists have discovered that stem cells loaded with the herpes virus can be used to specifically target and kill brain tumours.
Harvard Stem Cell Institute (HSCI) scientists at Massachusetts General Hospital have a potential solution for how to more effectively kill tumour cells using cancer-killing viruses.
The work, led by Khalid Shah, an HSCI Principal Faculty member, found that trapping virus-loaded stem cells in a gel and applying them to tumours significantly improved survival in mice with glioblastoma multiforme, the most common brain tumour in human adults and also the most difficult to treat (…)
Shah and his
Studies begun by Harvard Stem Cell Institute (HSCI) scientists eight years ago have led to a report published today that may be amount to a major step in developing treatments for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
The findings by Kevin Eggan, a professor in Harvard’s Department of Stem Cell and Regenerative Biology (HSCRB), and colleagues also has produced functionally identical results in human motor neurons in a laboratory dish and in a mouse model of the disease, demonstrating that modeling the human disease with customized stem cells in the laboratory could relatively soon eliminate some